Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 6
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
CLDN18.2 expression
gastric cancer · Small Molecule Inhibitor
CLDN18.2 expression is flagged as trial selection rising because public trials show inclusion required evidence in 7 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 5
Common snippets: MSI-H | MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 1
Recent signals: 1
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT07511894 | https://clinicaltrials.gov/study/NCT07621562 | https://clinicaltrials.gov/study/NCT06346197 | https://clinicaltrials.gov/study/NCT06222944 | https://clinicaltrials.gov/study/NCT06093425 | https://clinicaltrials.gov/study/NCT05482893 | https://clinicaltrials.gov/study/NCT05632939